Skip to content

Altimmune Announces Acceptance of HepTcell Abstract for Presentation at BSI/NVVI Congress 2016

GAITHERSBURG, Md., Dec. 06, 2016 (GLOBE NEWSWIRE) — Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that its abstract related to the development of an assay to detect low frequency antigen-specific T cells in HepTcell trial participants was accepted for presentation at the BSI/NVVI Congress 2016 taking place December 6 – 9, 2016 in Liverpool, U.K. HepTcell is Altimmune’s first-in-class T cell-activating immunotherapeutic in development for the treatment of chronic hepatitis B (CHB). A Phase 1 trial is currently underway.

The BSI/NVVI Congress 2016 is a joint collaboration between the British Society for Immunology (BSI) and the Dutch Society for Immunology (NVVI), two of Europe’s most established immunology organizations, to bring together the latest in cutting-edge immunology research.

The poster, entitled, “Development of a cultured ELISpot assay to detect low frequency antigen-specific T cells in PBMC from HBV therapeutic vaccine trial participants,will be presented by Verity Motskin on Thursday, December 8, 2016 from 5:30 – 7:30 PM GMT.

About Altimmune
Altimmune is a clinical stage immunotherapeutic company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines. Using these technologies, Altimmune has developed three novel clinical stage product candidates that potentially represent an entirely new approach to harnessing the immune system.

The Company’s most advanced product candidate, NasoVAX, is a Phase 2-ready intranasally-delivered recombinant influenza vaccine offering broad and rapid protection with potential for significant advantages over traditional flu vaccines. The second most advanced product candidate, HepTcell, is being tested as an immunotherapy for patients chronically infected with hepatitis B and has the potential to provide a functional cure. With the support of the U.S. Biomedical Advanced Research and Development Authority, or BARDA, the Company is developing a third product candidate, NasoShield, a first-in-class anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. The Company intends to leverage the RespirVec and Densigen platforms to develop additional product candidates for a variety of indications.


Bill Enright
President and CEO
Altimmune, Inc.
Phone: 240-654-1450

Investor Relations
Stephanie Carrington
ICR, Inc.
Phone: 646-277-1282

Source: Altimmune